0
Please log in or register to do it.

Samsung Bioepis

Samsung Bioepis

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Samsung Bioepis obtained product approval from the Ministry of Food and Drug Safety for ‘Apilibu’ (ingredient name: aflibercept), a biosimilar (biopharmaceutical copy) used for eye diseases. 23 The day was revealed.

Apilibu’s original medicine, ‘Eylea’, is a treatment for eye diseases developed by the American pharmaceutical company Regeneron and is used for macular degeneration and diabetic macular edema, which cause blindness in the elderly.

Samsung Bioepis has confirmed clinical equivalence to Eylea in the phase 3 clinical trial of Apilibu.

The company will be Samil Pharmaceutical in the future.[000520]We plan to sell this treatment domestically.

Jeong Byeong-in, head of the RA (licensing and licensing) team at Samsung Bioepis, said, “We have once again proven the company’s biopharmaceutical research and development capabilities through the approval of Apilibu, and we will strive to contribute to solving unmet medical needs in the domestic eye disease field in the future.” .

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/23 16:33 Sent

Entertech Bigk, MOU with Naver Cloud… Strengthening AI cooperation
Xiaomi Pad 6S Pro (with Snapdragon 8th generation)

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *